Parasites pose a threat to the health and lives of many millions of human beings. Among the pathogenic protozoa, Trypanosoma brucei, Trypanosoma cruzi, and Leishmania donovani are hemoflagellates that cause particularly serious diseases (sleeping sickness, Chagas disease, and leishmaniasis, respectively). The drugs currently available to treat these infections are limited by marginal efficacy, severe toxicity, and spreading drug resistance. Camptothecin is an established antitumor drug and a well-characterized inhibitor of eukaryotic DNA topoisomerase I. When trypanosomes or leishmania are treated with camptothecin and then lysed with SDS, both nuclear and mitochondrial DNA are cleaved and covalently linked to protein. This is consistent with the existence of drug-sensitive topoisomerase I activity in both compartments. Camptothecin also inhibits the incorporation of [3H]thymidine in these parasites. These molecular effects are cytotoxic to cells in vitro, with EC50 values for T. brucei, T. cruzi, and L. donovani, of 1.5, 1.6, and 3.2 ,uM, respectively. For
Parasites cause severely debilitating and fatal illness in millions of people throughout the world (1) . Among these organisms are the flagellated protozoa, which include the trypanosomes and leishmania. African trypanosomes (Trypanosoma brucei sp.) cause sleeping sickness, a meningoencephalitis that is ultimately lethal if not treated (2) . In large areas of South and Central America, Trypanosoma cruzi causes Chagas' disease, characterized by cardiomyopathy and massive dilatation of the esophagus and colon (3) . Leishmaniasis presents a spectrum of disease, ranging from self-limited cutaneous ulcers, to erosive and disfiguring mucocutaneous disease, to lethal visceral infections (4) . There are no effective drugs for Chagas' disease; the treatment of African trypanosomiasis and leishmaniasis typically involves the lengthy, parenteral administration of toxic agents (e.g., trivalent arsenicals, pentamidine, pentavalent antimonials); and resistant organisms are appearing. The need for new molecular targets on which to base future treatment strategies is clear and immediate.
In searching for such strategies, the DNA topoisomerases are attractive candidate targets. These enzymes have gained prominence not only because they are essential for the orderly synthesis of nucleic acids but also because they are the molecular site of action for numerous clinically important antibacterial and antitumor agents (e.g., the fluoroquinolones, etoposide, camptothecin). Topoisomerases mediate the topological manipulations of DNA required by cells during DNA replication and transcription (reviewed in refs. [5] [6] [7] . Two classes of enzymes are defined, based on their catalytic mechanism: type I topoisomerases make single-stranded breaks in DNA, whereas type II topoisomerases make double-stranded
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breaks. Both types may be inhibited by compounds that trap the enzyme in midreaction as a protein-DNA complex, termed a "cleavable complex" (8, 9) . When rapidly denatured (e.g., by SDS or alkali), cleavable complexes yield covalently linked DNA-protein adducts. In cells, the collision of DNA tracking machinery (involved in replication and transcription) with cleavable complexes is cytotoxic (10) (11) (12) .
Topoisomerases I and II have been studied in pathogenic hemoflagellates and closely related organisms. Topoisomerase II has been purified (13) (14) (15) (16) , and several topoisomerase II genes have been sequenced (17) (18) (19) . In previous studies, we found that topoisomerase II inhibitors promote extensive cleavage of nuclear and mitochondrial DNA in African trypanosomes, that some classical antitrypanosomal drugs are topoisomerase inhibitors, and that topoisomerase II inhibition is lethal to trypanosomes (20) (21) (22) (23) . Topoisomerase I has been purified from T cruzi (24) , Leishmania donovani (25) , and Crithidia fasciculata (a related parasite of insects). The Crithidia enzyme immunolocalizes to the nucleus, but not the mitochondrion (26) .
The mitochondrial DNA of trypanosomes and leishmania (termed kinetoplast DNA; kDNA) is a highly characteristic feature that is clearly visible in Giemsa-stained cells. As visualized by electron microscopy, purified kDNA is a massive network containing thousands of minicircles (-1 kb each) and several dozen maxicircles (-25 kb each) that are topologically interlocked with one another (see refs. 27-29 for reviews of kDNA). Manipulation of this massive and intricate structure during replication and transcription obviously entails numerous topological interconversions. Not surprisingly, trypanosome mitochondria contain large amounts of topoisomerase II (20) , and a type II topoisomerase that immunolocalizes only to the mitochondrion has been isolated (30) . However, efforts to purify a mitochondrial topoisomerase I in kinetoplastids have not succeeded, leading to the belief that kinetoplast-specific topoisomerases may be exclusively type II enzymes (26) .
The following studies were designed to determine whether inhibition of type I topoisomerases might have molecular and cytotoxic effects on hemoflagellate parasites. For these studies, we chose camptothecin, a chemotherapeutic agent that inhibits topoisomerase I from eukaryotes but not from prokaryotes (9) . To our knowledge, camptothecin has not previously been tested against topoisomerase I from kinetoplastids. We now demonstrate that camptothecin treatment of intact parasites yields protein-DNA adducts and that the drug is lethal to trypanosomes and leishmania. We also find that camptothecin traps minicircle DNA-protein complexes, providing evidence for the existence of a mitochondrial topoisomerase I in kinetoplastids. L. donovani (6 x 106 cells per ml; 26°C) were treated for 30 min with no drug or with 50 ,tM camptothecin and lysed with SDS as described above. The lysate was divided and treated with or without proteinase K (1.7 mg/ml; 1 hr; 50°C) before phenol extraction. Samples not digested with proteinase K developed a substantial interface between the aqueous and phenol layers. DNA in the aqueous layers of the extractions was precipitated with ethanol, subjected to electrophoresis through agarose, stained with ethidium bromide, and visualized by transillumination as described (20) .
MATERIALS AND METHODS
Analysis of Minicircle DNA. T. equiperdum were harvested from rats, suspended in medium, and treated (6 x (20) .
Cytotoxicity Assay. A modification of the acid phosphatase cytotoxicity assay (33) To test whether topoisomerase I inhibition blocks DNA synthesis in trypanosomatids, the incorporation of [3H]thymidine into T brucei bloodstream forms, T cruzi epimastigotes, and L. donovani promastigotes was monitored in the presence of camptothecin (Fig. 2) . A concentration-dependent inhibition of [3H]thymidine incorporation was observed for all three parasites at concentrations that generate cleavable complexes (Fig. 2) .
Camptothecin Promotes kDNA Minicircle Linearization. To evaluate the possibility that a drug-sensitive topoisomerase I might be present in the mitochondria of African trypanosomes, we examined the effect of camptothecin treatment on minicircle DNA. T. equiperdum were treated with 0.63% DMSO or 125 ,tM camptothecin (60 min; 37°C) and lysed with SDS. The purified DNA was resolved by agarose gel electrophoresis, blotted, and probed with radiolabeled minicircle DNA (20) . By this method, minicircles catenated in kDNA networks remain in the slot, and free minicircles, which are replication intermediates (36) , enter the gel. Control cells yield the usual population of free minicircles, consisting largely of monomeric forms that are nicked circles, covalently closed circles, or full-length linearized molecules (Fig. 3, lane 1) . Minicircle DNA from camptothecin-treated cells is clearly different (lane 2). First, there is an increase in the total mass of free minicircle DNA from camptothecin-treated cells (compare lanes 1 and 2; each lane contains DNA from the same number of cells). This indicates that minicircle DNA was released from networks into the free population. Second, there is a dramatic increase in the population of linearized minicircles. If the cell lysate is not digested with proteinase K prior to phenol extraction, the linearized minicircles are selectively lost from the aqueous phase of the extraction (lane 3). This is fully consistent with the notion that these molecules are covalently linked to protein and that they were generated from camptothecin-stabilized complexes between mitochondrial topoisomerase I and minicircle DNA in vivo.
Camptothecin Is Cytotoxic to Kinetoplastids. To determine whether formation of cleavable complexes and inhibition of nucleic acid biosynthesis are cytotoxic to kinetoplastid parasites, we developed a cytotoxicity assay for T. brucei and L. donovani that is simple, rapid, quantitative, and nonradioactive. This assay is based on the acid phosphatase-mediated production of p-nitrophenol (33) , which can be monitored in a microtiter plate reader. Dose-response curves yielded EC50 values with standard deviations of < 10% of the means, and R2 values for the fitted curves that were typically >0.95. Furthermore, the assay results agree well with those obtained from direct cell counts. We found that camptothecin is lethal to T. brucei and L. donovani, with EC50 values of 1.5 and 3.2 ,uM, respectively (Fig. 4) . These parasites were completely eliminated at high concentrations of camptothecin. Camptothecin is also cytotoxic for T. cruzi (Fig. 4) with an EC50 value of 1.6 ,uM, as determined from direct cell counts. For T. cruzi, a population of residual organisms persisted in the cell lysis debris, a common occurrence after drug treatment of this pleiomorphic parasite (37) . The. persistent organisms may represent a subpopulation that is inherently resistant to camptothecin or, more likely, the residual cells may be at a developmental stage that is transiently insensitive to the drug. 3) . The SDS lysates were incubated with proteinase K (lanes 1 and 2) or without proteinase K (lane 3) prior to phenol extraction. The DNA was partially purified prior to separation by electrophoresis (1.5% agarose in buffer containing 1 ,ug of ethidium bromide per ml) (20) . The DNA was transferred to GeneScreen, hybridized with 32P-labeled homologous minicircle DNA, washed, and exposed to x-ray film. Each lane contains DNA from 3 x 107 cells. Nicked/gapped minicircles (N), linearized minicircles (L), covalently closed circular minicircles (CC), and the slot (arrow) are indicated. (33) . Each (Fig. 5) . Its structure was elucidated in the mid-1960s (38) , and the first total synthesis of optically active 20(S)-camptothecin was reported in 1975 (39) . In 1985, the discovery that camptothecin stabilizes cleavable complexes in the cell, between topoisomerase I and DNA, provided a satisfying explanation for the well-characterized ability of the drug to generate protein-linked breaks in DNA (40) (41) , and it has proven a valuable tool for investigating the role of topoisomerase I in nucleic acid metabolism of eukaryotic cells (42, 43) . Camptothecin is selectively toxic for malignant cells in culture, it inhibits entirely the growth of human cancer xenographs in nude mice, and it overcomes MDR1-mediated resistance, properties that account for its high therapeutic index (44) (45) (46) . In clinical trials, the principal toxicity of orally administered therapeutic doses up to 8.7 mg/M2, given daily for several months, is diarrhea (47) . The array of analogs that have been synthesized (48) (49) (50) (51) , five of which are currently in clinical trials (52, 53) .
We find that camptothecin promotes the formation of nuclear DNA-protein adducts in trypanosomes and leishmania. This provides evidence that these pathogenic hemoflagellates, which are among the most ancient of the eukaryotes (54) (55) (56) , have camptothecin-sensitive topoisomerase I activity. Furthermore, and of obvious importance for chemotherapy, trypanosomes and leishmania are permeable to camptothecin. This contrasts with a number of other eukaryotes, including C. fasciculata (A.L.B., unpublished observation) and yeast (41) , which are unaffected by camptothecin concentrations of 100 ,uM or more. Not surprisingly, cleavable complexes in vivo are accompanied by inhibition of DNA synthesis (Fig. 2) .
More unexpected was the finding that camptothecin also promotes the formation of mitochondrial DNA-protein adducts. Minicircle DNA from trypanosomes treated with camptothecin shows a striking increase in the population of linearized, protein-bound, molecules (Fig. 3) . These linearized forms derive from kDNA networks, and they may arise if multiple molecules of topoisomerase I bind close to one another on opposite strands of the minicircle or if topoisomerase I binds across from one of the preexisting nicks or gaps present in newly replicated minicircles. Topoisomerase I may also bind to covalently closed minicircles; however, this reaction would yield protein-bound nicked circles, which would remain catenated to the network and trapped in the slot of the gel. Camptothecin-promoted cleavage of minicircle DNA is consistent with the notion that trypanosome mitochondria contain topoisomerase I activity, and that this activity is more akin to eukaryotic than to prokaryotic topoisomerase I.
We cannot be absolutely certain that in trypanosomes the only intracellular target of camptothecin is topoisomerase I. However, support for this view is provided by camptothecin's absolute specificity for topoisomerase I in other systems (41, 57) , by its inability to bind to DNA or to inhibit purified DNA or RNA polymerases (40, 58) , and by its lack of activity against purified topoisomerase II from T. brucei (T.A.S., unpublished observation).
Camptothecin is cytotoxic to T. brucei, T cruzi, and L. donovani in vitro, with EC50 values of 1-3 ,uM (Fig. 4) . These levels are within the range for other antitrypanosomal drugs in our assay (e.g, 0.02 and 22 ,uM for pentamidine and difluoromethylornithine, respectively). In other cells, camptothecin cytotoxicity is S-phase specific and appears to require a collision between the DNA replication machinery and the drug-trapped, topoisomerase I cleavable complex (10) (11) (12) . Aphidicolin, an inhibitor of DNA polymerase, partially protects T. brucei against camptothecin cytotoxicity. This suggests that a similar mechanism is operative in trypanosomes. The fact that aphidicolin affords incomplete protection may indicate that other DNA tracking processes (e.g., transcription) may also convert the cleavable complex into a cytotoxic lesion.
These studies support the concept that topoisomerase I is a suitable target for antiprotozoal chemotherapy and that camptothecin will be a valuable reagent for studying topoisomerase I in these organisms. In view of the severely limited resources available for development of new antiparasitic drugs (1, 59) , the rather broad spectrum of antiparasitic activity of camptothecin, unusual for drugs against kinetoplastid parasites, is especially attractive.
Research and Manufacturers of America Foundation Faculty Development Award (T.A.S.).
